Literature DB >> 32684068

Inhibitory activities of indolizine derivatives: a patent review.

Kamal M Dawood1, Ashraf A Abbas1.   

Abstract

INTRODUCTION: Indolizines are structural isomers with indoles. Although several indole-based commercial drugs are available in the market, none of the indolizine-based drugs are available up-to-date. Natural and synthetic indolizines have a wide-range of pharmaceutical importance such as antitumor, antimycobacterial, antagonist, and antiproliferative activities. This prompted us to search and collect all possible data about the pharmacological importance of indolizine to open an avenue to the researchers in exploring more medicinal applications of such biologically important compounds. AREAS COVERED: The current review article covers the advancements in the biological and pharmacological activities of indolizine-based compounds during the last decade. The covered areas of this work involved anticancer, anti-HIV-1, anti-inflammatory, antimicrobial, anti-tubercular, larvicidal, anti-schizophrenia, CRTh2 antagonist's activities in addition to enzymatic inhibitory activity. EXPERT OPINION: The discovery of indolizine drugs will be a major breakthrough as compared with their widely available drug-containing indole isosteres. Major work collected here was focused on anticancer, anti-tubercular, anti-inflammatory, and enzymatic inhibitory activities. The SAR study of the reported biologically active indolizines is summarized throughout the review whenever highlighted to the rationale the behavior of inhibitory action. Several indolizines with certain functions provided great enhancement in the therapeutic activities comparing with reference drugs.

Entities:  

Keywords:  Indolizines; anti-HIV; anticancer; antiinflammatory; antitubercular; enzymes inhibitors

Mesh:

Substances:

Year:  2020        PMID: 32684068     DOI: 10.1080/13543776.2020.1798402

Source DB:  PubMed          Journal:  Expert Opin Ther Pat        ISSN: 1354-3776            Impact factor:   6.674


  3 in total

1.  Access to 6-hydroxy indolizines and related imidazo[1,5-a]pyridines through the SN2 substitution/condensation/tautomerization cascade process.

Authors:  Guiyun Duan; Hao Liu; Liqing Zhang; Chunhao Yuan; Yongchao Li; Yanqing Ge
Journal:  RSC Adv       Date:  2021-07-23       Impact factor: 4.036

2.  Design and synthesis of new bis(1,2,4-triazolo[3,4-b][1,3,4]thiadiazines) and bis((quinoxalin-2-yl)phenoxy)alkanes as anti-breast cancer agents through dual PARP-1 and EGFR targets inhibition.

Authors:  Fatma M Thabet; Kamal M Dawood; Eman A Ragab; Mohamed S Nafie; Ashraf A Abbas
Journal:  RSC Adv       Date:  2022-08-19       Impact factor: 4.036

3.  Anti-tubercular activity and molecular docking studies of indolizine derivatives targeting mycobacterial InhA enzyme.

Authors:  Katharigatta N Venugopala; Sandeep Chandrashekharappa; Pran Kishore Deb; Christophe Tratrat; Melendhran Pillay; Deepak Chopra; Nizar A Al-Shar'i; Wafa Hourani; Lina A Dahabiyeh; Pobitra Borah; Rahul D Nagdeve; Susanta K Nayak; Basavaraj Padmashali; Mohamed A Morsy; Bandar E Aldhubiab; Mahesh Attimarad; Anroop B Nair; Nagaraja Sreeharsha; Michelyne Haroun; Sheena Shashikanth; Viresh Mohanlall; Raghuprasad Mailavaram
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.